קסופיגו - Xofigo

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)

V10XX
Various therapeutic radiopharmaceuticals

××¨××× ×¤×¢×× (ATC5)

Radium-223 dichloride 1100 KBQ/ML AT REFERENCE DATE âV10XX03

×¦××¨×ª ××ª×

×ª××-××¨××× - I.V

×¦××¨×ª ××× ××

×ª×××¡× ××××¨×§×, SOLUTION FOR INJECTION
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

Xofigo monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced PC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment.

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

12/01/2014

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª
××ª×¨××¤× ×ª×× ×ª× ××××¤×× ××¡×¨×× ××¨××¨×ª× ×©× ××¢×¨××× ××ª ×¢××× ××¡××¨××¡ (CRPC) ×××××× ×¡×××¤××××××× ×¢× ××¨××¨××ª ××¢×¦×××ª ×××× ×××× ×××¡×¨×××ª ××¨××¨×ª××ª.

××¡××¨×ª ××××× ××¡×

×. ××ª×¨××¤× ×ª×× ×ª× ××××¤×× ××¡×¨×× ××¨××¨×ª× ×©× ××¢×¨××× ××ª ×¢××× ××¡××¨××¡ (CRPC) ×××××× ×¡×××¤××××××× ×¢× ××¨××¨××ª ××¢×¦×××ª ×××× ×××× ×××¡×¨×××ª ××¨××¨×ª××ª.

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¨××¤× 16.12.2020

×¢××× ××¦×¨××	Â

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×§×¡××¤××× ×××××¨ ××©×¨× ×××¨××××ª ×§×¡××¤××× ×××××¨ ××©×¨× ×××¨××××ª ×§×¡××¤××× ×××××¨ ××©×¨× ×××¨××××ª ×§×¡××¤××× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	BAYER AS, NORWAY
×©× ××¢× ××¨××©××	BAYER ISRAEL LTD
×¨××©×××	×ª××¨×× ×××©×: 07/2013. ×¨××©××× ××ª××¨××: 03/2014
×ª××¨×× ×¢×××× ×××¨××	12/03/24

השינוי האחרון נעשה בֹ־12 במרץ 2024 ב־17:08

קסופיגו - Xofigo

ויקיתרופות